Hikal: Press Release- Hikal Signs Multi-Year Global CDMO Contract with Leading Agrochemical Company
Hikal (HIKAL) filed a disclosure titled "Press Release- Hikal Signs Multi-Year Global CDMO Contract with Leading Agrochemical Company". The company is valued at about ₹2,609 crore.
What happened
Hikal (HIKAL) filed a disclosure with the exchanges on 2 November 2026 at 08:06 AM titled "Press Release- Hikal Signs Multi-Year Global CDMO Contract with Leading Agrochemical Company".
Company snapshot
Hikal is a small-cap company, with a market value of about ₹2,609 crore.
The stock last traded at ₹211.6, against a 52-week range of ₹146.3–₹261 (18.9% below the high).
Before this filing the shares had moved −3.0% over the month and −4.4% over three months. Average daily turnover over the last 20 sessions was about ₹11.08 crore.
Promoters held 68.85% at the end of Q1 FY27. Foreign institutions owned 0.99% and domestic institutions 7.24%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 380 | -22.4 | -1.82 |
| Q2 FY26 | 319 | -34.9 | -2.83 |
| Q3 FY26 | 494 | -5.9 | -0.48 |
| Q4 FY26 | 519 | 14.4 | 1.17 |
| Q1 FY27 | 403 | -7.4 | -0.6 |
What history shows
BCEIE has no earlier approval filing from this company on record since May 2026.
Market-wide, 1,547 approval filings with an impact score of 50 or more saw an average next-day move of +0.1%, with 47% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- 3 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- Hikal Limited Estimates – NSE:HIKAL
- Hikal Ltd. Share Price Today - Hikal Ltd. Stock Price Live NSE/BSE
- Buzzing Stocks: Hikal share price gains 7% after securing Swissmedic GMP certification; InterGlobe...
- Hikal Limited (HIKAL.NS) Slips 5.50% to ₹192.0 — Support at ₹182.4 in Focus - Algorithmic Stock Picks
- Hikal NSE:HIKAL Q2 H1 FY27 Earnings Conference Call
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.